After grabbing 0.17 million shares, the institutional investor is now in possession of 0.17 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 9.83% having worth around $0.23 million. Moreover, The Vanguard Group, Inc. increased its share by 840.0 to have a control over 18981.0 shares. And Renaissance Technologies LLC raised its holdings to 3970.0 shares by acquiring 12601.0 shares or 0.75% of the stake.
NeuBase Therapeutics Inc. (NBSE) concluded trading on 09/14/23 at a closing price of $1.30, with 10.61 million shares of worth about $13.79 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -65.30% during that period and on Thursday the price saw a gain of about 5.69%. Currently the company’s common shares owned by public are about 1.69M shares, out of which, 1.43M shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 1 analysts are covering the NBSE stock and their offered price forecasts bring an average price target of $200.00. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $200.00 and could fall to a lowest price of $200.00. However, touching the estimated high of $200.00 would mean a gain of 99.35% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 4 times over the past 12 months. They bought 1,612,200 shares in 4 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Vanguard Extended Market Index Fu, Jacob Discovery Fund, and Fidelity Extended Market Index Fu are the top 3 mutual funds which are holding stakes in NeuBase Therapeutics Inc. Vanguard Extended Market Index Fu is currently holding 18981.0 shares of worth totaling $26384.0. The company recently came buying 0.0 shares which brought its stake up to 1.12% of the company’s outstanding shares. Fidelity Extended Market Index Fu, after buying 7080.0 shares, have now control over 0.42% of the stake in the company. It holds 0.0 shares of worth $9841.0.
NeuBase Therapeutics Inc. (NASDAQ: NBSE) started trading at $1.22, below -$0.01 from concluding price of the previous day. However, the stock later moved at a day high price of 1.8100, or with a gain of 5.69%. Stock saw a price change of -30.48% in past 5 days and over the past one month there was a price change of 88.95%. Year-to-date (YTD), NBSE shares are showing a performance of -65.83% which decreased to -88.77% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.61 but also hit the highest price of $12.35 during that period. The average intraday trading volume for NeuBase Therapeutics Inc. shares is 2.20 million. The stock is currently trading 21.75% above its 20-day simple moving average (SMA20), while that difference is up 2.75% for SMA50 and it goes to -60.64% lower than SMA200.
Armistice Capital LLC acquired 0.17 million shares of NeuBase Therapeutics Inc. having value of about $0.23 million. NeuBase Therapeutics Inc. (NASDAQ: NBSE) currently have 1.69M outstanding shares and institutions hold larger chunk of about 37.20% of that. Holding of mutual funds in the company is about 25.83% while other institutional holders and individual stake holders have control over 28.45% and 2.84% of the stake respectively.
The stock has a current market capitalization of $3.64M and its 3Y-monthly beta is at 0.81. It has posted earnings per share of -$11.85 in the same period. It has Quick Ratio of 2.50 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NBSE, volatility over the week remained 26.06% while standing at 32.19% over the month.
Analysts are in expectations that NeuBase Therapeutics Inc. (NBSE) stock would likely to be making an EPS of -$1.8 in the current quarter, while forecast for next quarter EPS is $0 and it is -$1.92 for next year. For the current quarter EPS, analysts have given the company a lowest target -$1.8 which is -$1.8 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$4.8 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 87.30% while it is estimated to decrease by -40.60% in next year. EPS is likely to shrink at an annualized rate of 4.00% for next 5-years, compared to annual growth of 51.00% made by the stock over the past 5-years.
Analysts at 1 brokerage firms have issued recommendations for the NeuBase Therapeutics Inc. (NBSE)’s stock and average of those rates the stock at a “Hold” and assign it a score of 3.00. Out of those 1 Wall Street analysts, 0 recommended a “Buy” rating, while 1 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on February 12, 2021 offering a Buy rating for the stock and assigned a target price range of between $15 and $18 to it.